| URL | https://www.fiercepharma.com/pharma/italian-plasma |
| Source | Fierce Pharma |
| Date Published | 09/29/2025 |
| Author Name | Kevin Dunleavy |
| Company/Division name | Kedrion Biopharma |
| Parent company | Kedrion Biopharma |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Capital investment ($): | 260 |
| City reshored to: | Melville |
| State(s) reshored to: | NY |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |